ArticleBMC rheumatology2026
Health-related quality of life among people with rheumatic and musculoskeletal diseases in Cyprus: a cross-sectional study of disease burden and time since diagnosis.
Article in BMC rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatic and musculoskeletal diseases (RMDs) profoundly affect health-related quality of life (HRQoL), imposing a significant distinct burden on physical and mental well-being. Given the high prevalence and long-term disability associated with RMDs, understanding their impact is essential for informing public health priorities. This study aims to delineate the multifaceted impact of RMDs on HRQoL across diverse disease categories and examine how the impact on HRQoL varies by diagnosis and time since diagnosis.
methodsThis cross-sectional study (July 2023 - July 2024) employed a mixed sampling approach, combining a stratified sample of participants from clinical settings with an open call through online channels to reach a broader population of individuals with RMD in Cyprus. Physical (PCS) and Mental Component Scores (MCS) of the SF-12 questionnaire were used to assess HRQoL. Demographic and clinical variables, including age, gender, marital status, smoking status, and time since diagnosis were recorded. Multivariable regression analyses were used to explore differences in HRQoL scores by disease group and time since diagnosis, adjusting for demographic characteristics.
resultsThe study enrolled 789 participants (mean age 55.4 ± 13.2 years, 76.6% female). Among participants, 57.4% reported low PCS (< 40) and 38.7% reported low MCS (< 40). Fibromyalgia demonstrated the most pronounced HRQoL impairments, with significantly lower scores, compared to inflammatory diseases, for both physical (B = - 11.45; 95% CI: - 15.06, - 7.83) as well as mental components of HRQoL (B = - 12.31; 95% CI: - 16.18, - 8.4). Notable reductions in PCS and MCS were also recorded among patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) reflecting the systemic and psychological burden of these conditions. Marked HRQoL reductions were recorded among participants in early disease stages (0-2 years), while those with a longer time since diagnosis (2-10 years) demonstrated relative improvements.
conclusionRMDs significantly impact HRQoL, with substantial variability across disease categories and time since diagnosis. While the cross-sectional nature of the study does not capture trajectories across stages of disease progression, the significant and differential by disease category impairment in HRQoL at the early stages emphasize the need for disease-specific, multidisciplinary care approaches and highlight the critical importance of early diagnosis and optimized management to mitigate the long-term impact of RMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.